The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people ...

The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The potential payout relates to an earlier deal over tax evasion by U.S. clients of Credit Suisse, the rival Swiss bank that UBS acquired in 2023. Seven & i reported a drop in quarterly net profit but ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Gritmind, a leading software consultancy specializing in custom product development, data strategy, and AI, is pleased to announce a significant investment from four new shareholders. This investment ...